Status:
UNKNOWN
The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
Lead Sponsor:
Meir Medical Center
Conditions:
Hemoptisis
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood. Massive hemoptysis variab...
Eligibility Criteria
Inclusion
- Age \> 18
- Hemodynamicaly stable
- Hemoptysis of varying etiologies
- Coumadin treatment will be switched to clexane or heparine
Exclusion
- Age \< 18
- Hemodinamicaly unstable
- Massive hemoptysis ( \> 200 ml / day)
- Renal failure: creatinine \> 3, renal replacement treatment
- Hepatic failure: bilirubin \> 2 mg/dl, AST \> 3 of upper normal limit level
- Coagulation disorders, INR\> 2.
- Hypesensitivity to tranexamic acid
- Pregnant woman
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01496196
Start Date
January 1 2012
End Date
February 1 2016
Last Update
April 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pulmonary department, Meir Medical Center
Kfar Saba, Israel, Israel, 972